Literature DB >> 19150387

Angiotensin II and the development of insulin resistance: implications for diabetes.

J Alberto Olivares-Reyes1, Araceli Arellano-Plancarte, J Ramon Castillo-Hernandez.   

Abstract

Angiotensin II (Ang II), the major effector hormone of the renin-angiotensin system (RAS), has an important role in the regulation of vascular and renal homeostasis. Clinical and pharmacological studies have recently shown that Ang II is a critical promoter of insulin resistance and diabetes mellitus type 2. Ang II exerts its actions on insulin-sensitive tissues such as liver, muscle and adipose tissue where it has effects on the insulin receptor (IR), insulin receptor substrate (IRS) proteins and the downstream effectors PI3K, Akt and GLUT4. The molecular mechanisms involved have not been completely identified, but the role of serine/threonine phosphorylation of the IR and IRS-1 proteins in desensitization of insulin action has been well established. The purpose of this review is to highlight recent advances in the understanding of Ang II actions which lead to the development of insulin resistance and its implications for diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19150387     DOI: 10.1016/j.mce.2008.12.011

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  64 in total

1.  Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.

Authors:  Pavan K Battiprolu; Thomas G Gillette; Zhao V Wang; Sergio Lavandero; Joseph A Hill
Journal:  Drug Discov Today Dis Mech       Date:  2010

Review 2.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 3.  Insulin resistance, hyperglycemia, and atherosclerosis.

Authors:  Karin E Bornfeldt; Ira Tabas
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

4.  Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and β-klotho expression decrease with fasting in northern elephant seals.

Authors:  Miwa Suzuki; Andrew Y Lee; José Pablo Vázquez-Medina; Jose A Viscarra; Daniel E Crocker; Rudy M Ortiz
Journal:  Gen Comp Endocrinol       Date:  2015-04-07       Impact factor: 2.822

5.  Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging.

Authors:  Anne-Emilie Declèves; Joshua J Rychak; Dan J Smith; Kumar Sharma
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-18

6.  Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling.

Authors:  Anna M Papinska; Maira Soto; Christopher J Meeks; Kathleen E Rodgers
Journal:  Pharmacol Res       Date:  2016-03-05       Impact factor: 7.658

7.  Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery.

Authors:  Shun Watanabe; Takayuki Matsumoto; Mirai Oda; Kosuke Yamada; Junya Takagi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2015-11-17       Impact factor: 3.657

Review 8.  Perinatal taurine exposure affects adult arterial pressure control.

Authors:  Sanya Roysommuti; J Michael Wyss
Journal:  Amino Acids       Date:  2012-10-16       Impact factor: 3.520

9.  Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways.

Authors:  Aung Than; Melvin Khee-Shing Leow; Peng Chen
Journal:  J Biol Chem       Date:  2013-04-16       Impact factor: 5.157

10.  Type II diabetes increases mitochondrial DNA mutations in the left ventricle of the Goto-Kakizaki diabetic rat.

Authors:  S Hicks; N Labinskyy; B Piteo; D Laurent; J E Mathew; S A Gupte; J G Edwards
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-02-01       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.